证券记录 · 已归档季度
NVAX
Novavax, Inc. · Healthcare · Biotechnology
19被追踪持有人
+2Δ持有人
55.31M持有股份
$479.50M报告持仓市值
+2新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +11.8% ·
股份流向 +4.0% ·
净新建仓位 +10.5%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 11.37K | $125,080 | n/a | n/a |
| Q2 2026 | 98 | +3 | 79.12M | $745.13M | +11 | −8 |
| Q1 2026 | 98 | +8 | 80.71M | $656.76M | +12 | −4 |
| Q4 2025 | 89 | -3 | 88.45M | $594.43M | n/a | −3 |
| Q3 2025 | 19 | +2 | 55.31M | $479.50M | +2 | n/a |
| Q2 2025 | 14 | 0 | 51.16M | $322.31M | n/a | n/a |
| Q1 2025 | 11 | +1 | 21.46M | $137.59M | +1 | n/a |
| Q4 2024 | 10 | -2 | 20.61M | $165.71M | n/a | −2 |
| Q3 2024 | 11 | +2 | 17.18M | $216.96M | +2 | n/a |
| Q2 2024 | 9 | n/a | 15.07M | $190.77M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (被动) | 15.19M | -1.6% | $131.74M | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (被动) | 12.77M | +0.2% | $110.74M | 0.0% | ▲ Add | 2 | SEC ↗ ×12 |
| 3 | State Street Global Advisors ✦ (被动) | 7.20M | +5.5% | $62.40M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 4.27M | +8.4% | $37.06M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 5 | Coatue Management ✦ | 3.84M | 0.0% | $33.27M | 0.1% | Held | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (被动) | 3.79M | +0.6% | $32.88M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Millennium Management ✦ | 2.13M | +5.2% | $18.44M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 1.29M | +55.1% | $11.15M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Renaissance Technologies ✦ | 1.20M | +79.2% | $10.38M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 10 | Morgan Stanley ✦ | 1.08M | n/a | $9.33M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 11 | Goldman Sachs Group ✦ | 789.28K | n/a | $6.84M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Two Sigma Investments ✦ | 702.00K | +30.2% | $6.09M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 328.64K | +13.4% | $2.85M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 14 | T. Rowe Price ✦ | 191.07K | +4.3% | $1.66M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 179.71K | +921.1% | $1.56M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 16 | JPMorgan Chase ✦ | 146.04K | n/a | $1.27M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 17 | Point72 Asset Management ✦ | 96.92K | 新增 | $840,266 | 0.0% | New | 1 | SEC ↗ ×2 |
| 18 | Wellington Management ✦ | 67.15K | +5.9% | $582,155 | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 19 | Marshall Wace ✦ | 50.59K | 新增 | $438,659 | 0.0% | New | 1 | SEC ↗ ×2 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Point72 Asset Management | $840,266 | 0.0% |
| Marshall Wace | $438,659 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 1 持有人, 100.30K 股份, $816 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据